MOPIDAMOL

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C19H31N7O4
Molecular Weight	421.4939
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OCCN(CCO)C1=NC2=C(N=C(N=C2C=N1)N(CCO)CCO)N3CCCCC3

InChI

InChIKey=FOYWNSCCNCUEPU-UHFFFAOYSA-N

InChI=1S/C19H31N7O4/c27-10-6-25(7-11-28)18-20-14-15-16(22-18)17(24-4-2-1-3-5-24)23-19(21-15)26(8-12-29)9-13-30/h14,27-30H,1-13H2

HIDE SMILES / InChI

Molecular Formula	C19H31N7O4
Molecular Weight	421.4939
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2830407 | https://adisinsight.springer.com/drugs/800004627 | http://www.armchairpatriot.com/Encyclopedias/Encyclopedia-Pharmaceutical%20Manufacturing%20(3rd%20edition)/15265_v03_06.pdf | https://www.ncbi.nlm.nih.gov/pubmed/4062970 | https://www.ncbi.nlm.nih.gov/pubmed/8304965

Mopidamol (RA-233, Rapenton), a derivative of dipyridamole, is a phosphodiesterase inhibitor that has been shown previously to limit progression of malignancy in certain experimental animal models and in a pilot study in humans. It was indicated for the treatment of cancer metastases. RA-233 treatment was associated with a statistically significant prolongation of survival in patients with non-small cell lung cancer (N-SCLC) limited to one hemithorax and with reduction in mean plasma fibrogen concentration. RA-233 was not toxic. Mopidamol was launched in Germany in 1980 as Rapenton® for the prevention of postoperative metastases after surgery on primary sarcomas and lymphomas. Mopidamol is thromboxane receptor antagonist and immunostimulant. Its development for the treatment of non-small cell lung cancer, ovarian cancer and yhrombosis was discontinued.

Originator

Approval Year

PubMed

Title	Date	PubMed
Effect of mopidamol on survival in carcinoma of the lung and colon: final report of Veterans Administration Cooperative Study No. 188.	1988-03-16	2830407

Patents

Sample Use Guides

In Vivo Use Guide

Rats: Mopidamol, 8.3 mg/kg/day, caused 50.6% inhibition of ADP-induced platelet aggregation, 37.6% inhibition of aggregation induced with arachidonic acid, a 47.6% decrease in serum levels of thromboxane B2 and a 23.7% increase in the vascular production of 6-keto-PGF1 alpha, versus saline-treated rats.

Route of Administration: Oral

In Vitro Use Guide

According to its concentrations, RA-233 had inhibitory or lethal effect on L 1210 cells. After 24 hr of culture, LC50, and IC50 were, respectively, 5 x 10 (-4) moles/l and 2 x 10 (-4) moles/l. After 48 hr of cultures, IC50 was 1 x 10 (-4) mole/l. With highly toxic concentrations (i.e. 10 (-3) mole/l) lethality became perceptible only after 4 hr of culture, then grew sigmoidally to reach 50 per cent after 8 hr and more than 90 per cent after 12 hr.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:57:01 GMT 2025` Edited by `admin` on `Mon Mar 31 17:57:01 GMT 2025`
Record UNII	4Q0IWP8B8O
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MOPIDAMOL

Official Name

English

MOPIDAMOL [MI]

Preferred Name

English

MOPIDAMOL [MART.]

Common Name

English

mopidamol [INN]

Common Name

English

Mopidamol [WHO-DD]

Common Name

English

2,2',2'',2'''-((4-PIPERIDINOPYRIMIDO(5,4-D)PYRIMIDINE-2,6-DIYL)DINITRILO)TETRAETHANOL

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C2019